Clinical characteristics of the DLBCL cohorts at diagnosis
| Clinical characteristic . | Training series (n = 163) . | Validation series (n = 145) . | P . |
|---|---|---|---|
| Age > 60 y | 104/163 (63.8%) | 96/145 (66.2%) | .659 |
| Male:female | 92:71 | 66:79 | .056 |
| ECOG PS > 1 | 21/163 (12.9%) | 23/145 (15.9%) | .456 |
| Ann Arbor stage | .301 | ||
| I | 34/163 (20.9%) | 25/145 (17.2%) | — |
| II | 44/163 (27.0%) | 51/145 (35.2%) | — |
| III | 29/163 (17.8%) | 18/145 (12.4%) | — |
| IV | 56/163 (34.4%) | 51/145 (35.2%) | — |
| B symptoms | 38/163 (23.3%) | ||
| Bulky | 46/163 (28.2%) | 37/145 (25.5%) | .593 |
| Extranodal sites > 1 | 41/163 (25.2%) | 28/145 (19.3%) | .220 |
| LDH > ULN | 54/163 (33.1%) | 66/145 (45.5%) | .931 |
| IPI | .526 | ||
| Low | 80/163 (49.1%) | 65/145 (44.8%) | — |
| Low-intermediate | 34/163 (20.9%) | 33/145 (22.8%) | — |
| High-intermediate | 25/163 (15.3%) | 29/145 (20.0%) | — |
| High | 24/163 (14.7%) | 18/145 (12.4%) | — |
| Non-GC phenotype | 53/127 (41.7%) | ||
| Bone marrow function | |||
| ANC, ×109/L | 4.5 (3.6-5.7) | — | — |
| Hb, g/dL | 12.9 (11.8-14.1) | — | — |
| Platelets, ×109/L | 256 (206-320) | — | — |
| Liver, renal, and cardiac function | |||
| Albumin, g/L | 4.1 (3.7-4.4) | — | — |
| ALP, U/L | 174 (147-233) | — | — |
| Bilirubin, mg/dL | 0.7 (0.5-0.9) | — | — |
| Glomerular filtration rate, mL/min | 61 (48-77) | — | — |
| Cardiac ejection fraction, % | 59 (55-64) | — | — |
| Comorbidities | |||
| Charlson Comorbidity Index | 1 (0-2) | — | — |
| Clinical characteristic . | Training series (n = 163) . | Validation series (n = 145) . | P . |
|---|---|---|---|
| Age > 60 y | 104/163 (63.8%) | 96/145 (66.2%) | .659 |
| Male:female | 92:71 | 66:79 | .056 |
| ECOG PS > 1 | 21/163 (12.9%) | 23/145 (15.9%) | .456 |
| Ann Arbor stage | .301 | ||
| I | 34/163 (20.9%) | 25/145 (17.2%) | — |
| II | 44/163 (27.0%) | 51/145 (35.2%) | — |
| III | 29/163 (17.8%) | 18/145 (12.4%) | — |
| IV | 56/163 (34.4%) | 51/145 (35.2%) | — |
| B symptoms | 38/163 (23.3%) | ||
| Bulky | 46/163 (28.2%) | 37/145 (25.5%) | .593 |
| Extranodal sites > 1 | 41/163 (25.2%) | 28/145 (19.3%) | .220 |
| LDH > ULN | 54/163 (33.1%) | 66/145 (45.5%) | .931 |
| IPI | .526 | ||
| Low | 80/163 (49.1%) | 65/145 (44.8%) | — |
| Low-intermediate | 34/163 (20.9%) | 33/145 (22.8%) | — |
| High-intermediate | 25/163 (15.3%) | 29/145 (20.0%) | — |
| High | 24/163 (14.7%) | 18/145 (12.4%) | — |
| Non-GC phenotype | 53/127 (41.7%) | ||
| Bone marrow function | |||
| ANC, ×109/L | 4.5 (3.6-5.7) | — | — |
| Hb, g/dL | 12.9 (11.8-14.1) | — | — |
| Platelets, ×109/L | 256 (206-320) | — | — |
| Liver, renal, and cardiac function | |||
| Albumin, g/L | 4.1 (3.7-4.4) | — | — |
| ALP, U/L | 174 (147-233) | — | — |
| Bilirubin, mg/dL | 0.7 (0.5-0.9) | — | — |
| Glomerular filtration rate, mL/min | 61 (48-77) | — | — |
| Cardiac ejection fraction, % | 59 (55-64) | — | — |
| Comorbidities | |||
| Charlson Comorbidity Index | 1 (0-2) | — | — |
The 25th to 75th percentiles are reported in parentheses for continuous variables.
CG indicates germinal center; ANC, absolute neutrophil count; Hb, hemoglobin; ALP, alkaline phosphatase; and —, not applicable.